repare therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. its approach integrates insights from several fields of cell biology including dna repair and synthetic lethality. repare’s platform combines a proprietary, high throughput, crispr‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics. the company is backed by leading global healthcare investors including founding investor versant ventures and mpm capital. for additional information, please visit www.reparerx.com.
Company profile
Ticker
RPTX
Exchange
Website
CEO
Lloyd M. Segal
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Repare Therapeutics USA Inc. ...
RPTX stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
8-K
Termination of a Material Definitive Agreement
12 Feb 24
8-K
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
25 Jan 24
8-K
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
12 Jan 24
8-K
Regulation FD Disclosure
15 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Regulation FD Disclosure
13 Oct 23
Latest ownership filings
4
Lloyd Mitchell Segal
1 Apr 24
4
Steve Forte
1 Apr 24
4
Michael Zinda
1 Apr 24
4
Maria Koehler
1 Apr 24
4
Steve Forte
27 Mar 24
4
Michael Zinda
27 Mar 24
4
Maria Koehler
27 Mar 24
4
Lloyd Mitchell Segal
27 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
144
Notice of proposed sale of securities
26 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 107.37 mm | 107.37 mm | 107.37 mm | 107.37 mm | 107.37 mm | 107.37 mm |
Cash burn (monthly) | 2.73 mm | 3.99 mm | 12.81 mm | 8.75 mm | 10.96 mm | 10.72 mm |
Cash used (since last report) | 18.70 mm | 27.35 mm | 87.88 mm | 60.04 mm | 75.19 mm | 73.57 mm |
Cash remaining | 88.67 mm | 80.02 mm | 19.49 mm | 47.33 mm | 32.18 mm | 33.80 mm |
Runway (months of cash) | 32.5 | 20.1 | 1.5 | 5.4 | 2.9 | 3.2 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 77 |
Opened positions | 8 |
Closed positions | 10 |
Increased positions | 22 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 427.10 bn |
Total shares | 48.87 mm |
Total puts | 63.70 k |
Total calls | 1.06 mm |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 8.29 mm | $0.00 |
BVF | 8.29 mm | $100.17 bn |
Orbimed Advisors | 3.32 mm | $40.14 bn |
Deep Track Capital | 3.07 mm | $37.06 bn |
CHI Advisors | 2.97 mm | $35.84 bn |
Versant Venture Management | 2.65 mm | $31.97 bn |
ARK Investment Management | 2.62 mm | $31.66 bn |
Redmile | 2.40 mm | $29.05 bn |
MPM Asset Management | 2.24 mm | $27.09 bn |
MPM BioVentures 2014 | 2.24 mm | $76.41 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Maria Koehler | Common Shares | Sell | Dispose S | No | Yes | 4.66 | 300 | 1.40 k | 231,409 |
1 Apr 24 | Michael Zinda | Common Shares | Sell | Dispose S | No | Yes | 4.66 | 410 | 1.91 k | 71,908 |
1 Apr 24 | Steve Forte | Common Shares | Sell | Dispose S | No | Yes | 4.61 | 789 | 3.64 k | 44,775 |
1 Apr 24 | Lloyd Mitchell Segal | Common Shares | Sell | Dispose S | Yes | Yes | 4.63 | 2,491 | 11.53 k | 107,558 |
28 Mar 24 | Maria Koehler | Common Shares | Sell | Dispose S | No | Yes | 4.64 | 500 | 2.32 k | 231,709 |
28 Mar 24 | Michael Zinda | Common Shares | Sell | Dispose S | No | Yes | 4.64 | 450 | 2.09 k | 72,318 |
28 Mar 24 | Steve Forte | Common Shares | Sell | Dispose S | No | Yes | 4.62 | 825 | 3.81 k | 45,564 |
28 Mar 24 | Lloyd Mitchell Segal | Common Shares | Sell | Dispose S | Yes | Yes | 4.62 | 2,650 | 12.24 k | 110,049 |
27 Mar 24 | Lloyd Mitchell Segal | Common Shares | Sell | Dispose S | Yes | Yes | 4.63 | 2,650 | 12.27 k | 83,866 |
26 Mar 24 | Lloyd Mitchell Segal | Common Shares | Sell | Dispose S | Yes | Yes | 4.64 | 2,650 | 12.30 k | 86,516 |
News
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
15 Apr 24
HC Wainwright & Co. Reiterates Buy on Repare Therapeutics, Maintains $10 Price Target
8 Mar 24
Recap: Repare Therapeutics Q4 Earnings
28 Feb 24
HC Wainwright & Co. Reiterates Buy on Repare Therapeutics, Maintains $10 Price Target
21 Feb 24
HC Wainwright & Co. Maintains Buy on Repare Therapeutics, Lowers Price Target to $10
14 Feb 24
Press releases
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
15 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
7 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
3 Mar 24
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
29 Feb 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
28 Feb 24